Skip to main content

Table 1 Baseline clinical characteristics of the 3 groups

From: Impact of post-challenge hyperglycemia on clinical outcomes in japanese patients with stable angina undergoing percutaneous coronary intervention

  DM (n=452) PH (n=236) NGT (n=140) P value
Age, years 70 (62–74)* 67 (59–72) 69 (62–74) 0.002
Male 347 (76.7) 203 (86.0)†‡ 103 (73.5) 0.004
Hypertension 380 (84.0) 185 (78.3) 104 (74.2) 0.019
Dyslipidemia 295 (65.2) 164 (69.4) 101 (72.1) 0.24
Current smoking 119 (26.3) 74 (31.3) 34 (24.2) 0.24
Previous PCI 249 (55.0)*† 104 (44.0) 66 (47.1) 0.015
Previsou CABG 33 (7.2) 9 (3.8) 10 (7.1) 0.18
Previous MI 148 (32.7) 63 (26.6) 39 (27.8) 0.2
Previous CI 55 (12.1) 27 (11.4) 11 (7.8) 0.36
Multivessel disease 128 (28.3) 59 (25.1) 29 (20.7) 0.18
BMI, kg/m2 24.3 (22.1-26.4)† 24.7 (22.9-26.6)† 23.2 (21.0-25.7) <0.001
LVEF, % 61.0 (50.0-68.0)* 64.0 (55.0-69.0) 64.0 (50.2-68.0) 0.017
eGFR, ml/min./1.73m2 64.9 (51.4-76.1) 66.2 (57.5-75.1) 65.6 (54.6-79.6) 0.17
Stent type     0.057
BMS 255 (56.4) 146 (61.8) 94 (67.1)  
DES 197 (43.6) 90 (38.2) 46 (32.9)  
Medication at discharge     
Aspirin 452 (100.0) 236 (100.0) 140 (100.0) -
Thienopyridine 452 (100.0) 236 (100.0) 140 (100.0) -
β-blocker 136 (30.0) 78 (33.0) 41 (29.2) 0.66
ACE-I 117 (25.8) 48 (20.3) 27 (19.2) 0.12
ARB 178 (39.3) 86 (36.0) 46 (32.8) 0.33
Statin 285 (63.0) 139 (58.9) 79 (56.4) 0.29
OHA 325 (71.9) 0 (0.0) 0 (0.0) <0.001
Insulin 64 (14.1) 0 (0.0) 0 (0.0) <0.001
  1. Values are expressed as medians (interquartile range) or number and percentage. *P <0.05 vs. PH; †P <0.05 vs. NGT; and ‡P <0.05 vs. DM.
  2. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body-mass index; BMS, bare-metal stent; CABG, coronary artery bypass graft; CI, cerebral infarction; DES, drug-eluting stent; DM, diabetes mellitus; eGFR, Estimated glomerular filtrating ratio; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NGT, normal glucose tolerance; OHA, oral hypoglycemia agent; PCI, percutaneous coronary intervention; PH, post-challenge hyperglycemia.